Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review-Reference-Cited by-同舟云学术

Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review

Published:2021-06 Issue: Volume:162 Page:103336
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Hirte Hal,Yao Xiaomei^ORCID,Ferguson Sarah E.,May Taymaa,Elit Laurie^ORCID

Funder

Cancer Care Ontario

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference49 articles.

1. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study;Alberts;Gynecol. Oncol.,2006

2. Prospero;Anon,2021

3. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer;Berek;J. Clin. Oncol.,2004

4. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer;Berek;J Immunother.,2008

5. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer;Berek;J. Clin. Oncol.,2009

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: Germline BRCA 2 mutation in primary peritoneal carcinoma: a rare malignancy;Frontiers in Oncology;2024-09-03

2. Evaluating the efficacy of artificial intelligence tools for the automation of systematic reviews in cancer research: A systematic review;Cancer Epidemiology;2024-02

3. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-04-18

4. Study Design Solutions for Adjuvant and Maintenance Therapy in Cancer: Ovarian Cancer as an Example;SN Comprehensive Clinical Medicine;2022-08-13

5. Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective;Cancer Drug Resistance;2022